Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 33 - BALLAD
2024-515299-11-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine, fluorouracil, oxaliplatin and folinic acid in small bowel adenocarcinoma (SBA) (3 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
capecitabinefluorouraciloxaliplatinfolinic acid
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on 2024-515299-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515299-11-00.